Efficacy of selected targeted strategies in relapsed or refractory mantle cell lymphoma (MCL).
| Author, year . | Regimen . | n . | Response rates, OR . | Median PFS . | Median OS . |
|---|---|---|---|---|---|
| PFS indicates progression-free survival; OS, overall survival; ORR, overall response rate; CR(u), complete response (unconfirmed) rate; N.a., not available. | |||||
| Wang 200943 | Ibritumomab d 8 Rituximab 375 mg/m2 | 34 | 31% | 6 mo | 21 mo |
| O’Connor 200947 | Bortezomib 1.5 mg/m² d 1, 4, 8, 11 | 40 | 47% (CR/CRu: 13%) | 5.3 mo | n.a. |
| Goy 200946 | Bortezomib 1.3 mg/m² d 1, 4, 8, 11 | 141 | 33% (CR/CRu: 8%) | 6.5 mo | 23.5 mo |
| Kaufmann 200449 | Thalidomide 200 mg Rituximab 375 mg/m2 | 16 | 81% (CR/CRu: 31%) | 20.4 mo | 75% (3 y) |
| Habermann 200950 | Lenalidomide 25 mg d 1–21 | 15 | 53% (CR/CRu: 20%) | 5.6 mo | n.a. |
| Zinzani 200851 | Lenalidomide 25 mg d 1–21 | 39 | 43% (CR/CRu: 8%) | 7.2 mo | n.a. |
| Witzig 200552 | Temsirolimus 250 mg weekly | 35 | 38% (CR/CRu: 3%) | 6.5 mo | 12 mo |
| Hess 200853 | Temsirolimus 175 mg/75mg weekly | 54 | 22% | 4.8 mo | 13.6 mo |
| Temsirolimus 175 mg/25mg weekly | 54 | 6% | 3.4 mo | 10 mo | |
| Lin 200854 | 40–60 mg d 1 (-3) Fludarabine 25 mg/m2 d 1–5 Rituximab 375 mg/m2 d 1 | 10 | 80% (CR/Cru: 70%) | 32.3 mo (only responders) | n.a. |
| Author, year . | Regimen . | n . | Response rates, OR . | Median PFS . | Median OS . |
|---|---|---|---|---|---|
| PFS indicates progression-free survival; OS, overall survival; ORR, overall response rate; CR(u), complete response (unconfirmed) rate; N.a., not available. | |||||
| Wang 200943 | Ibritumomab d 8 Rituximab 375 mg/m2 | 34 | 31% | 6 mo | 21 mo |
| O’Connor 200947 | Bortezomib 1.5 mg/m² d 1, 4, 8, 11 | 40 | 47% (CR/CRu: 13%) | 5.3 mo | n.a. |
| Goy 200946 | Bortezomib 1.3 mg/m² d 1, 4, 8, 11 | 141 | 33% (CR/CRu: 8%) | 6.5 mo | 23.5 mo |
| Kaufmann 200449 | Thalidomide 200 mg Rituximab 375 mg/m2 | 16 | 81% (CR/CRu: 31%) | 20.4 mo | 75% (3 y) |
| Habermann 200950 | Lenalidomide 25 mg d 1–21 | 15 | 53% (CR/CRu: 20%) | 5.6 mo | n.a. |
| Zinzani 200851 | Lenalidomide 25 mg d 1–21 | 39 | 43% (CR/CRu: 8%) | 7.2 mo | n.a. |
| Witzig 200552 | Temsirolimus 250 mg weekly | 35 | 38% (CR/CRu: 3%) | 6.5 mo | 12 mo |
| Hess 200853 | Temsirolimus 175 mg/75mg weekly | 54 | 22% | 4.8 mo | 13.6 mo |
| Temsirolimus 175 mg/25mg weekly | 54 | 6% | 3.4 mo | 10 mo | |
| Lin 200854 | 40–60 mg d 1 (-3) Fludarabine 25 mg/m2 d 1–5 Rituximab 375 mg/m2 d 1 | 10 | 80% (CR/Cru: 70%) | 32.3 mo (only responders) | n.a. |